Advanced Search


Study ID Status Title Patient Level Data
116863 Completed A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Study Listed on
116878 Terminated Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures Study Listed on
116881 Withdrawn Inflammatory mediator release from epithelial cells taken from Japanese COPD patients, smoking controls and non-smoking controls
116882 Not yet recruiting Anti-inflammatory effects of salmeterol, fluticasone propionate and the combination in epithelial cells from Japanese COPD patients
116883 Completed Study of chronic obstructive pulmonary disease (COPD) prevalence in Japanese subjects with smoking history who are aged 40 years or older and consulting periodically for cardiovascular disease
116885 Completed A Japanese open-label Phase I/II study to assess the safety, tolerability, pharmacokinetics and efficacy of GSK2118436 and GSK1120212 combination therapy in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part).
116886 Completed Observer-blind study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A in adults 18 years of age or older with renal transplant
116887 Completed Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Boostrix® in adults aged 50 years and older
116889 Completed Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23™ in adults aged 50 years and older Study Listed on
116891 Completed A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers Study Listed on
116892 Relinquished Immunogenicity and safety study of 1 and 2 doses of GSK Biologicals’ meningococcal vaccine GSK134612 in toddlers, persistence up to 5 years after vaccination and co-administration with Pfizer's pneumococcal vaccine Prevenar 13™
116895 Completed Healthcare seeking behaviour of primary caregivers for acute otitis media in children aged 6 months to less than 30 months in Panama
116897 Completed A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Study Listed on
116898 Completed A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects
116910 Relinquished OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris
116911 Completed Indirect Treatment Comparison to Inform the Evaluation of the Cost-Effectiveness of Lapatinib plus Letrozole for First-Line Treatment of Post-Menopausal Women with Hormone Receptor Positive and HER-2 Positive Metastatic Breast Cancer from Canadian Societal and Healthcare System Perspectives
116913 Completed A Burden-of Illness Study in Patients with Stage IB-IIIA Non–small Cell Lung Cancer (NSCLC)
116914 Completed Administrative Database Study on the Impact of Adherence to Drug Therapy in Asthma Patients Treated with ADVAIR or Fluticasone Propionate in Quebec
116926 Completed Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) when administered in children Study Listed on
116929 Completed A study to assess the impact of rotavirus vaccination on hospitalizations and outpatient visits due to rotavirus gastroenteritis (RV GE) in Japan
116931 Recruiting Systematic Review and Meta-Analysis: Retigabine for Adjunctive Therapy in Partial Epilepsy – updated review for Canada
116932 Active, not recruiting Drug Use Investigation for MALARONE Combination Tablets - Investigation on Malaria (Treatment and Prevention)
116935 Completed PGx6049: Pharmacogenetic Evaluation of Steroid Response in Fluticasone Furoate and Fluticasone Propionate Treated Asthma Subjects
116937 Completed Open,two-period, two-treatment, two-sequence, cross-over, randomized trial of single doses of two oral preparations with 0.25 mg of Alprazolam (Zamoprax® GlaxoSmithKline México, S.A. de C.V. vs. Tafil® 0.25mg, Pharmacia &Upjohn, S.A. de C.V.) in fasting healthy volunteers
116938 Completed An observer-blind, dose ranging safety and immunogenicity study of GSK Biologicals’ GSK1557484A vaccine in children 6 to less than 36 months of age



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.